Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Gasparetto on Managing Keratopathy Associated With Belantamab Mafodotin in Myeloma

December 15th 2021

Cristina Gasparetto, MD, discusses how to manage keratopathy associated with treatment with belantamab mafodotin-blmf in patients with multiple myeloma.

Cilta-cel Elicits Early, Deep Responses in Heavily Pretreated, Lenalidomide-Refractory Myeloma

December 15th 2021

A single infusion of ciltacabtagene autoleucel produced an overall response rate of 95% in patients with multiple myeloma who had received a median of 2 prior lines of treatment and who were refractory to lenalidomide.

Cilta-Cel Demonstrates Durable Responses at 2 Years Across Multiple Subgroups in R/R Myeloma

December 14th 2021

Data from a longer follow-up analysis of the phase 1/2 CARTITUDE-1 trial demonstrated that all evaluated subgroups of patients with relapsed/refractory multiple myeloma maintained durable responses with ciltacabtagene autoleucel.

Dr. Martin on the 2-Year Follow-Up Results of the CARTITUDE-1 Study in R/R Multiple Myeloma

December 14th 2021

Thomas G. Martin, MD, discusses the 2-year follow-up data of the phase 1/2 CARTITUDE-1 study in relapsed/refractory multiple myeloma, that were presented during the 2021 ASH Annual Meeting & Exposition.

Efficacy of Cevostamab Increases With Higher Doses in Heavily Pretreated Multiple Myeloma

December 14th 2021

Cycle 1 double step-up dosing with cevostamab demonstrated encouraging activity with effective cytokine release syndrome mitigation in patients with heavily pretreated relapsed/refractory multiple myeloma, supporting further development of the dual-targeted bispecific antibody.

Venetoclax-Based Triplet Continues to Confer Tolerable Safety, Deep Responses in t(11;14) Relapsed/Refractory Multiple Myeloma

December 14th 2021

Venetoclax at either 400 mg or 800 mg plus daratumumab and dexamethasone elicited deep durable responses and was associated with a tolerable safety profile in patients with t(11;14) relapsed/refractory multiple myeloma.

Interventions Needed to Improve QoL, Reduce Psychological Distress in Patients With Myeloma

December 14th 2021

Prognostic awareness was associated with higher rates of psychosocial distress and symptom burden, and lower quality of life in patients with multiple myeloma.

Lower Doses of Selinexor Plus Bortezomib and Dexamethasone Show Best Efficacy and Safety in Myeloma

December 14th 2021

Lower 60mg and 40mg doses of Selinexor in combination with bortezomib and dexamethasone demonstrated improved efficacy and safety vs a 100mg dose for patients with relapsed or refractory multiple myeloma.

Dr. Biran on the Results of an Arm of the STOMP Trial in R/R Multiple Myeloma

December 13th 2021

Noa Biran, MD, discusses the results of an arm of the ongoing phase 1b/2 STOMP trial evaluating selinexor, dosed at 40 or 60 mg, in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.

Cilta-Cel Continues to Impress With Durable and Deep Responses in Relapsed/Refractory Multiple Myeloma

December 13th 2021

Ciltacabtagene autoleucel elicited a 97.9% objective response rate and an 82.5% stringent complete response rate in patients with relapsed/refractory multiple myeloma at a median of approximately 2 years of follow-up.

Higher-Dosed Selinexor Plus Pomalidomide and Dexamethasone Demonstrates Efficacy in Relapsed/Refractory Multiple Myeloma

December 13th 2021

The 60mg phase 2 dose of selinexor plus pomalidomide and dexamethasone produced more durable and deep responses than the lesser selinexor dose for relapsed or refractory multiple myeloma.

Cilta-Cel Produces Deep Responses as Second-Line Treatment in Early Relapse Myeloma

December 13th 2021

A single infusion of ciltacabtagene autoleucel produced early and deep responses and encouraging minimal residue disease negativity in patients with multiple myeloma who experienced early clinical relapse following initial therapy.

Cilta-Cel Provides Superior Option Vs Standard Regimens in Triple-Class Exposed Multiple Myeloma

December 13th 2021

Comparative data from the phase 1 CARTITUDE-1 trial and the real-world LocoMMotion study demonstrated that ciltacabtagene autoleucel bested standard options for patients with triple-class exposed multiple myeloma.

Venetoclax/Selinexor Combo Shows Efficacy in Relapsed/Refractory Multiple Myeloma With t(11;14)

December 13th 2021

Selinexor combined with venetoclax demonstrated efficacy and tolerability in heavily pretreated relapsed/refractory multiple myeloma cell lines with t(11;14), according to small study results that were presented during the 2021 ASH Annual Meeting.

Cilta-cel Shows Greater Clinical Benefit Than SOC in Triple-Class Relapsed/Refractory Myeloma

December 12th 2021

Ciltacabtagene autoleucel demonstrated a significant advantage over physician’s choice of treatment with regard to overall survival, progression-free survival, time to next treatment, and overall response rate, underscoring its potential for use in patients with triple-class relapsed/refractory multiple myeloma.

Daratumumab/IRd Quadruplet Is Safe and Effective as Induction, Consolidation for Standard-Risk Myeloma

December 12th 2021

Extended induction and consolidation therapy with daratumumab plus ixazomib, lenalidomide, and dexamethasone led to deepening rates of minimal residual disease for patients with standard-risk, transplant-eligible newly diagnosed multiple myeloma.

MRD-Guided Therapy Could Inform Treatment-Free Surveillance in Newly Diagnosed Multiple Myeloma

December 12th 2021

Minimal residual disease, assessed through next-generation sequencing was found to inform treatment selection and duration with daratumumab plus carfilzomib, lenalidomide, and dexamethasone following autologous transplant in patients with newly diagnosed multiple myeloma.

Weekly Selinexor/Bortezomib/Dexamethasone Combo Demonstrates Favorable Efficacy and Safety in High-Risk Multiple Myeloma

December 12th 2021

Weekly selinexor plus bortezomib and dexamethasone represents a favorable option for patients with multiple myeloma and any cytogenetic profile, based on comparable objective responses rates and progression-free survival results from 2 clinical trials.

Selinexor Plus D-Vd Shows Promising Results and Safety in Patients With Relapsed or Refractory Multiple Myeloma

December 12th 2021

Selinexor in combination with daratumumab, bortezomib and dexamethasone demonstrated a manageable safety profile and encouraging efficacy in patients with late- and early-relapsed multiple myeloma.

Daratumumab Plus VTd Enhances MRD-Negativity Rates in Transplant-Eligible Myeloma

December 11th 2021

Minimal residual disease–negativity rates were significantly higher after utilizing daratumumab plus bortezomib, thalidomide, and dexamethasone (VTd) vs VTd alone in patients with newly diagnosed, transplant-eligible multiple myeloma, according to findings from the phase 3 CASSIOPEIA study that were presented at the 2021 ASH Annual Meeting and Exposition.